News & Views
Clinical Labelling Specialist Announces Five New Business Wins
Feb 09 2021
PRISYM ID’s Chief Executive Richard Adams has said that to meet the unique labelling and product information needs of the life science industry it has never been more important for regulated labelling technology companies to draw on deep, specialised knowledge and experience of the sector to enable it to continue to deliver the unmatched standards that patient safety and outcome demand.
Setting out his ambitions for 2021, Mr Adams said that there were important opportunities for clinical research and medical devices companies to build on the ingenuity applied throughout supply chains in response to COVID19 and that the unique complexities and challenges involved meant that he would continue to focus the company’s efforts squarely on supporting the life science and medical device sectors to deliver the specialised knowledge and solutions they value most.
It comes as PRISYM ID announces five new business wins for the start of 2021, with new accounts spanning clinical trials, pharmaceutical and medical device sectors and with significant growth of the company’s flagship PRISYM 360 platform in the Cloud.
“It is clear to me that the pandemic will leave a lasting legacy for the life science industry. It has fundamentally re-written the rules in terms of what we now think is feasible in terms of speed-to-market of new products and has probably raised expectations considerably.
“The challenge now is to lock in these gains. I’m conscious that PRISYM ID has learnt so much working with our clients in this environment, and I want to make sure we maintain a laser-like focus on both the medical device and life sciences sectors as we help them reconfigure after COVID.
“From my perspective, specialisation is a key part of this: it’s never been more important for supply chain partners to understand the terrain, know the challenges and be able to operate as intelligent business partners to pharma, CROs and med tech firms as they negotiate their way forward in 2021. We have to listen even harder to understand how companies visualise their operating practices going forward but the great news is, I know PRISYM ID is positioned better than anyone to respond and deliver the regulated labelling and content management solutions they need.
“Above all else, being a life science and medical device sector specialist is our passion and core purpose at PRISYM ID - it’s really important to me and the whole team that this remains our singular focus, and I think these new business wins show that it’s also a very powerful proposition for the market.”
Mr Adams leadership approach focuses the company to collaborate with customers and users, to understand the pressures they face as they develop, market and ship products, whilst regulatory demands change. He sees this as a key differentiator to make sure the PRISYM ID technology and expertise is continually focused on helping customers to reduce risk, deliver efficiencies, and ensure compliance.
More information onlineâ¯
In This Edition Chromatography Optimising Viral Vector Purification Strategies with Multimodal Chromatography Key UHPLC Characteristics Required for High throughput LC-MS New Low Volum...
View all digital editions
Dec 20 2022 Shanghai, China & Online 21 November 2022 to 13 January 2023
Jan 25 2023 Tokyo, Japan
Jan 30 2023 Dubai, UAE
Feb 01 2023 Tokyo, Japan
Feb 06 2023 Dubai, UAE